false000004907100000490712020-02-202020-02-20 

 [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

500 W. Main Street, Louisville, Kentucky 40202 

(Address of Principal Executive Offices, and Zip Code) 

(502) 580-1000 

Registrant’s Telephone Number, Including Area Code 

(Former Name or Former Address, if Changed Since Last Report)  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)    

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)    

      ☐

    Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))    

      ☐

    Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))    

  [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).  

Emerging growth company ☐  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

  Item 5.02   

Departure of Directors or Certain Officers; Election of Directors; Appointment of 

Certain Officers; Compensatory Arrangements of Certain Officers.    

(d) Effective February 19, 2020, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from ten to twelve and elected Wayne A.I. Frederick, M.D., and John W. Garratt as directors of the Company. 

The Board of Directors has determined that (i) Dr. Frederick and Mr. Garratt are each independent within the meaning of the New York Stock Exchange’s director independence standards; (ii) there have been no arrangements or understandings between either Dr. Frederick or Mr. Garratt and any other persons pursuant to which either Dr. Frederick or Mr. Garratt was selected as a director; and (iii) there are no material transactions involving either Dr. Frederick or Mr. Garratt and the Company. 

Dr. Frederick and Mr. Garratt will each be compensated in accordance with the Company’s standard compensation policies and practices for the Board, the components of which were disclosed by the Company in its proxy statement filed with the U.S. Securities and Exchange Commission on March 6, 2019. In connection with their elections to the Board, Dr. Frederick and Mr. Garratt also will be granted restricted stock units (RSUs) in accordance with the Company’s director compensation program. Dr. Frederick and Mr. Garratt have not yet been appointed to any committees of the Board. 

On February 20, 2020, the Company issued a press release announcing the elections of Dr. Frederick and Mr. Garratt, a copy of which is attached hereto as Exhibit 99.1, and is incorporated by reference herein. 

Item 9.01 Financial Statements and Exhibits. 

(d) Exhibits: 

  [DATA_TABLE_REMOVED] 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED] 

Dated: February 20, 2020